in-pharmatechnologist presents a roundup of the latest drug sector manufacturing expansions with Sanofi Aventis, Takeda, Cerbios and Alliance Medical all adding capacity.
Sanofi to build €75m plant in Algeria
French drug major Sanofi Aventis will build a production plant in Algeria after receiving clearance from the country’s government.
According to a report on El Khabar the new manufacturing facility will make a range of pharmaceutical for distribution and sale across Algeria where Sanofi already has an 18 per cent share of the market.
Sanofi will operate the facility in partnership with Algerian state owned drug manufacturing firm Saidal.
Takeda plans 24h production at new Y14bn plant
Takeda says new Y14bn ($163m) Japan plant will offer round-the-clock drug manufacturing capacity when operational in April 2012.
The facility, construction of which is scheduled to begin next month, will be adjacent to Takeda’s existing manufacturing complex in Hikari City, Yamaguchi Prefecture and is intended make oral solid dose drugs in large volumes.
Osaka-headquartered Takeda said the additional capacity will enable it to “achieve economical cost structure and also to fully respond to the required level of quality control that is becoming more and more sophisticated.”
The firm also stressed the “24 hour a day production capacity” as a key benefit, explaining that such operations give it the flexibility to respond to changes in the business environment.
Alliance Medical adds high-volume vial filling line
US CMO Alliance Medical Products has installed a new high-volume drug vial filling line at its facility in Irvine, California
The new line, which has the capacity to produce up to 150,000 vials in a single production shift, is supported by an inline vial washer, depyrogenation tunnel and 12 spindle capper. The line also features nitrogen purge or blanket and vial sizes ranging from 2mL to 150mL.
Juan Valdes, CEO of the contract manufacturing organisation (CMO) said: “The addition of this line further extends our ability to provide a complete range of developmental, clinical and commercial contract manufacturing services to large and small organizations."
Cerbios opens new high potency API plant
Swiss contract manufacturer Cerbios Pharma has opened a new high potency active pharmaceutical ingredient (API) manufacturing plant in Lugano.
The new plant, which can produce APS for low-dose drugs, houses separate synthesis, drying and isolation capacity as well as a floor dedicated to chromatography, wharehousing and repackging space.
The plant is the latest part of a decade long stragety that has seen Cerbios build capacity in HPAPI production in response to increased pharmaceutical industry focus on oncology and cytotoxics.